hpn217
abbvie
['mmsm', 'hpn217', 'multiple myeloma']
phase 1 study of hpn217:tritac targeting bbcma for rrmm: efficacy in rrmm; n=62; triple class 78%; 20% bcma exposed; the higher dose showed a rr of 77% #mmsm #ash22 #medtwitter 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter